Create account

Coverage dated October 8, 2026

Viatris is buying Pacira BioSciences for $1.65 billion in non-opioid pain push

Headline from Quartz

The deal, at $36.50 per share, represents a roughly 45% premium and is expected to close by the end of 2026

Quartz's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

3 articles, oldest first.

  1. Independent Journal Review

    Viatris agrees to acquire Pacira for $1.65B (opens Independent Journal Review)

    Published

    Independent Journal Review's feed description

    Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, valuing the company at about $1.65 billion and offering shareholders a roughly 45% premium. The deal, expected to close by the end of 2026 pending shareholder tenders and regulatory clearance, would add Pacira’s non-opioid pa…

  2. Investor's Business Daily

    Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly (opens Investor's Business Daily)

    Published

    Investor's Business Daily's feed description

    Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.

  3. Quartz

    Viatris is buying Pacira BioSciences for $1.65 billion in non-opioid pain push (opens Quartz)

    Published

    Quartz's feed description

    The deal, at $36.50 per share, represents a roughly 45% premium and is expected to close by the end of 2026

Viatris is buying Pacira BioSciences for $1.65 billion in non-opioid pain push | Since Then